Search PubMed⌕ Search

Biomedical subjects

R Amerling

Publications and source records attributed to R Amerling.

16 recordsLinked to original sources
PubMed2006

The ''Ronco'' catheter for continuous flow peritoneal dialysis.

To perform CFPD, a two way access must be available in order to allow continuous inflow and outflow of the solution. This is most likely achieved with a double lumen peritoneal catheter. To design a double lumen catheter does not necessarily mean to increase the size of the tube or to increase the discomfort of the patient. However, the real challenge is to find a design in which minimal re-circulation is experienced. The two tips of the catheter must be positioned such that a maximal exposure of the peritoneal surface to the fluid is guaranteed during one single passage of the fluid from one lumen to another. Double lumen catheters with one short branch and another long of straight and of spiral shape were originally designed. Ash and coworkers have designed a catheter with a t-shape configuration in order to distantiate to the maximum the tips of the two lumens. Recently we have designed a novel catheter for CFPD equipped with a thin walled silicone diffuser used to gently diffuse the inflow dialysate into the peritoneum. The holes on the round tapered diffuser are positioned to allow dialysate to perpendicularly exit 360 degrees from the diffuser. The diffuser design and hole locations disperse the high-flow dialysate fluid at 360 degrees, reducing trauma to the peritoneal walls and allowing the dialysate to mix into the peritoneum. The dispersed fluid infused into the peritoneal cavity is then drained through the second lumen whose tip is placed into the lower Douglas cavity. The new catheter with diffuser is also equipped with a special removable hub that allows for easy creation of the subcutaneous tunnel without increasing the size of the skin exit site. The results so far achieved seems to offer advantages in terms of high flows, minimal pressure regimes and negligible recirculation.

Catheterization↗
PubMed2003

Continuous flow peritoneal dialysis: a new double lumen catheter.

Continuous flow peritoneal dialysis (CFPD) is a therapy originally utilized in the sixties. It was then abandoned because of technical reasons, but, today, a new interest in this technique is emerging, because of new technical solutions and new hardware capabilities. CFPD is a peritoneal dialysis technique in which a certain amount of fluid is maintained in the peritoneal cavity, while a continuous inflow and outflow is provided via twin catheters or through a double lumen catheter. In this paper a new double lumen catheter is presented. The catheter is characterized by the presence of a diffuser in the inflow lumen, while a standard coiled shape characterizes the outflow lumen. The diffuser allows the use of high dialysate flows without peritoneal damage and with an excellent distribution of the fluid. The other feature of the catheter is the removable hub which allows for an easy subcutaneous tunneling of the catheter with a subsequent connection to the y segment. The special shape also guarantees a minimum recirculation during treatment. Data obtained in the first implanted catheter showed a progressive increase in small solute clearances in relation to an increase of the flow and the tidal volume in the peritoneal cavity. In particular, urea clearances up to 48 ml/min and creatinine clearances up to 39 ml/min were obtained. No major complications were observed after one year of use of the catheter.

Catheters, Indwelling↗
PubMed1999

High clearance continuous renal replacement therapy with a modified dialysis machine.

Recent studies suggest that the dialysis dose significantly affects survival in acute renal failure (ARF) patients and that bicarbonate dialysate improves acid-base balance during continuous renal replacement therapy (CRRT). These data inspired us to use slow continuous dialysis (SCD) in the treatment of ARF. SCD is defined by the following parameters: (a) blood flow (Q(B)) = 100 to 200 ml/min, (b) dialysate flow (Q(D)) = 100 to 300 ml/min, (c) the use of a modified hemodialysis machine with controlled ultrafiltration and online production of bicarbonate-based dialysate, and (d) continuous or extended daily treatment for 8 to 24 hours. SCD provides a urea clearance in the 70 to 80 ml/min range. Preliminary data from an ongoing clinical trial demonstrate the safety, efficiency, and simplicity of the treatment.

Acute Kidney Injury↗
PubMed1997

Laparoscopic salvage of malfunctioning peritoneal catheters.

BACKGROUND: Malfunction of peritoneal catheters due to mechanical outflow problems is an annoying complication in patients undergoing chronic peritoneal dialysis (PD). Correction often involves catheter replacement or revision via laparotomy. METHODS: Twenty-five patients undergoing PD who developed mechanical catheter flow restriction underwent 28 laparoscopic procedures. Preoperative diagnoses were made by contrast catheter radiography and were: catheter sequestration (36%), omental wrap (64%). Pneumoperitoneum was induced after general anesthesia and laparoscopy was performed using a Storz laparoscope. The catheter was then identified and manipulation was attempted using instruments placed percutaneously. RESULTS: In 26 cases (93%), the catheter was freed and function restored. In two cases (7%), adhesions were so numerous and dense that the distal catheter could not be visualized. Four episodes of peritonitis developed subcutaneous leakage of peritoneal fluid which responded to cessation of PD for 2 weeks. Four patients had recurrent occlusions; three of these were managed laparoscopically. Two patients developed late hernias at the site of insertion of the laparoscope. Catheter patency averaged 9.2 months postoperatively. CONCLUSIONS: Laparoscopic revision is a successful technique for salvage of occluded peritoneal catheters.

Adult↗
PubMed1993

Rapid progression of mitral and aortic stenosis in a patient with secondary hyperparathyroidism.

A 68 year old woman with chronic renal failure on long-term haemodialysis presented with progressive dyspnoea. Serial echocardiography showed a rapid reduction in mitral valve area from 2.18 to 0.92 cm2 over 18 months. In addition, the previously non-stenotic aortic valve was found to be severely stenotic with a valve area of 1.05 cm2. Cardiac catheterisation confirmed these findings. The patient had undergone subtotal parathyroidectomy more than 10 years before but had chemical and clinical evidence consistent with recurrent hyperparathyroidism. The patient underwent successful mitral and aortic valve replacement with relief of symptoms. Rapid progression of both aortic and mitral valve stenosis in the presence of secondary hyperparathyroidism is a rare finding.

Aged↗
PubMedDate not supplied

Clinical experience with continuous flow and flow-through peritoneal dialysis.

Concern over the inherent inefficiency of solute removal by conventional peritoneal dialysis (PD) has led to renewed interest in continuous flow PD (CFPD). We present clinical data from two experiences with CFPD. In the first, two catheters were used to recirculate a fixed intraperitoneal volume through an external circuit comprised of a standard hemodialysis system. The second patient had a dual-lumen PD catheter and was studied during two sessions of flow-through PD (FTPD) using sterile PD solution. Urea clearances with both techniques were around 30 ml/min, which is consistent with data reported in the literature. Significant streaming of dialysate from port to port within the peritoneal cavity limited clearances. CFPD offers a potentially safe and effective alternative to daily or nightly home hemodialysis.

Catheterization↗
PubMedDate not supplied

A new laparoscopic method for implantation of peritoneal catheters.

The placement of peritoneal catheters by non-surgeons was facilitated by a percutaneous laparoscopic technique ("Y-tec"). We have developed a catheter implantation system that is simpler to use, is less expensive initially and per procedure, and provides greatly enhanced peritoneal visualization. The core of the system is a 4 mm diameter Verres needle, which has a protective spring loaded obturator. This fits within a stainless steel cannula, which is in turn surrounded by a disposable peel away sheath. This entire unit is inserted into the peritoneal cavity through the rectus muscle after blunt dissection. Pneumoperitoneum is optional. The Verres needle is removed and peritoneoscopy is performed with a 5 mm Storz laparoscope. This is withdrawn, followed by the steel cannula, leaving the peel away sheath. The catheter is inserted through this, over a stylet. The sheath is then peeled off and the catheter sutured and tunneled in the usual fashion. This method uses the safest mode of blind peritoneal entry and permits thorough peritoneal inspection, even without insufflation. The needle and cannula are reusable, which minimizes cost. The technique is simple, and early results with inexperienced operators are encouraging.

Catheters, Indwelling↗
PubMedDate not supplied

The incident patient cohort study design with uncontrolled dose. Substantial over-estimation of mortality as a function of peritoneal dialysis dose?

In the Canada-USA (CANUSA) Study, the dialysis dose was neither randomized nor held constant, was measured at 6 month intervals, and the relative risk of mortality (R) was found to correlate linearly to mean values of weekly peritoneal plus renal urea clearance normalized to volume, (KprT/ V)m, ranging from 1.5 to 2.3. A risk/dose (R/D) function was derived for continuous ambulatory peritoneal dialysis from kinetic criteria for dose equivalency in hemodialysis (HD) and peritoneal dialysis (PD) and the HD R/D function. This PD R/D function was nonlinear with breakpoint from steep to shallow slope at (KprT/V)ud = 2.00, where ud refers to uniform single doses in contrast to mean doses with wide variances on the mean. The predicted decrease in renal urea clearance KrT/V per 6 months of CANUSA follow-up was computed from serial measured KrT/V in the Randomized Dialysis Prescription and Clinical Outcomes Study and showed it to be 0.21 +/- 0.34. The CANUSA (KprT/V)m values were corrected for the distributed values of 3 months decrements in KrT/V, and the population mortality risk at each (KprT/V)m dose level reported in CANUSA was computed from summation of the product of the R/D curve and fractional distribution of (KprT/V)ud values. From these calculations, the authors conclude that maximum (KprT/V)ud level achieved in CANUSA was 2.00, and the study does not define R/D response above this level.

Analysis of Variance↗